Oncogene News and Research

RSS

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.

New research suggests power of zebrafish as tool for cancer drug discovery

The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes.

24 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Researchers use CRISPR screen to reveal new targets in squamous cell carcinomas

A little p63 goes a long way in embryonic development - and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs.

18 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Gene considered as tumor promoter may also halt development of cancer, shows study

A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer.

9 Aug 2018

New drug delivery system delivers anticancer drugs that reduce tumor size

Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.

9 Aug 2018

MGH researchers explore how genetic abnormality in Ewing sarcoma unleashes tumor growth

A Massachusetts General Hospital research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma - the second most common bone cancer in children and young adults - unleashes tumor growth.

2 Aug 2018

Research uncovers new target for therapeutic intervention in breast cancer

Research led by Suresh Alahari, PhD, Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an emerging hallmark of cancer. The finding identifies a new target for therapeutic intervention in breast cancer.

18 Jul 2018

Researchers reveal massive genome havoc in breast cancer

In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations -- larger-scale rearrangements of DNA that can encompass large chunks of chromosomes -- disturb carefully balanced mechanisms that have evolved to regulate cell growth.

13 Jul 2018

Targeting amino acid transporter may improve survival rates for non-small cell lung cancer patients

An amino acid transporter named xCT may affect the growth and progression of non-small cell lung cancer, a discovery that may predict the five-year survival rate of patients suffering from this cancer, now at 16 percent, researchers at Georgia State University and Vanderbilt University Medical Center have concluded.

11 Jul 2018

Study explores occurrence and treatment of brain metastases in ROS1 lung cancer

Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.

10 Jul 2018

Mount Sinai study identifies potential new treatment target for aggressive bladder cancer

A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report.

4 Jul 2018

New biomarker paves way for personalized bladder cancer treatments

Researchers have identified a potential new target for the treatment of a particularly aggressive form of bladder cancer, in the form of microRNA.

2 Jul 2018

Canadian researchers uncover new molecular mechanism to stop proliferation of cancer cells

Canadian researchers have discovered a new and direct molecular mechanism to stop cancer cells from proliferating. In the prestigious journal Nature Cell Biology, scientists from Université de Montréal show that a disruption of a fine balance in the composition of ribosomes (huge molecules that translate the genetic code into proteins) results in a shutdown of cancer cell proliferation, triggering a process called senescence.

26 Jun 2018

New RNA deletion tool could help create drugs that correct genetic diseases

As scientists gain insights into which genes drive diseases, they are pursuing the next logical question: Can gene editing technologies be developed to treat or even cure those diseases? Much of that effort has focused on developing technologies such as CRISPR-Cas9, a protein-based system.

30 May 2018

Researchers use spheroids to screen for potential cancer drugs

Researchers from The Scripps Research Institute have reported a new and more effective way of screening for potential cancer drugs.

14 May 2018

Researchers target telomerase for killing NRAS-mutant melanoma cells

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

26 Apr 2018

Salk researchers develop new glioblastoma model using gene-edited organoids

Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.

25 Apr 2018

Role of extrachromosomal pieces of DNA in cancer development and treatment resistance

Glioblastoma is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent.

24 Apr 2018

Researchers discover potential hurdle for personalized medicine

A recent study has shown that loss of the Erk oncogene can stimulate tumorigenesis in cells where Ras has been eliminated. The findings may have important consequences for the development of personalized medicines that target Ras.

17 Apr 2018